Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

Author： Irshad S.   Gillett C.   Pinder S.   A’Hern R.   Dowsett M.   Ellis I.   Bartlett J.   Bliss J.   Hanby A.   Johnston S.   Barrett-Lee P.   Ellis P.   Tutt A.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.144, Iss.2, 2014-04, pp. : 331-341

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial

By Gluz Oleg  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 643-651

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

By Abe Hajime  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required

By Lakhanpal Roopa   Stuart-Harris Robin   Chan Arlene   Kotasek Dusan   Beith Jane   Cuff Katharine   Bastick Patricia   Lee Clara  

Breast Cancer Management, Vol. 2, Iss. 5, 2013-09 ,pp. : 367-374

Future Medicine

Access to resources Recommend Favorite